Latest studies
- RecruitingPHASE3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
This study looks at a new medicine called zilebesiran for people with high blood pressure that isn't well controlled, especially if they also have heart problems or are at high risk of developing them. The aim is to see if zilebesiran can reduce serious heart-related events like heart attacks or strokes.
High Risk Cardiovascular DiseaseHypertensionHigh Cardiovascular RiskNew Zealand - RecruitingPHASE3
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
This study looks at an inhaled medicine called treprostinil for people with progressive pulmonary fibrosis. It aims to see if it's safe and effective in slowing down this lung condition over 52 weeks. Half get the medicine, half get a dummy treatment.
Progressive Pulmonary FibrosisInterstitial Lung DiseaseNew Zealand - Active not recruitingPHASE3
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate
This study looks at a new drug called darolutamide, along with standard treatments like radiotherapy and hormone therapy, for men with prostate cancer that's at a very high risk of coming back. The aim is to see if this combination can better stop the cancer from spreading and improve their long-term health.
Prostate CancerNew Zealand - Recruiting
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
This study looks at how well Medtronic heart devices, like pacemakers and defibrillators, perform over a long time. It helps ensure these devices are reliable and safe for people with heart conditions such as irregular heartbeats or heart failure.
ArrhythmiaBradycardiaHeart FailureSinus TachycardiaNew Zealand - Recruiting
Exploring the hidden burden of living with Glanzmann thrombasthenia
This study wants to hear from people living with Glanzmann thrombasthenia (GT) and their caregivers. We want to understand the daily challenges and feelings of those affected. Your stories can help improve support and understanding for everyone with GT.
Glanzmann thrombastheniaNew Zealand - Active not recruitingPHASE3
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
This study is looking at a new medicine called Dazodalibep for people with Sjögren's Syndrome. It aims to see how well it helps with symptoms and whether it's safe to use, especially for those with moderate to severe symptoms.
Sjögren's Syndrome (SS)New Zealand - Active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
This study looks at a new combination of drugs, pembrolizumab and enzalutamide, for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. It compares this combination to enzalutamide alone to see if it helps men live longer and stops the cancer from growing.
Prostatic NeoplasmsNew Zealand - Active not recruitingPHASE1, PHASE2
A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD
This study looks at a new medicine called WVE-006 for a genetic lung and liver condition called Alpha-1 Antitrypsin Deficiency (AATD). It aims to see if the medicine is safe, how much good it does, and how the body handles it in people with AATD.
Alpha-1 Antitrypsin DeficiencyNew Zealand - RecruitingPhase III
Astria STAR-0215-302 trial for Navenibart in Hereditary Angioedema
This study looks at a new medicine called navenibart for hereditary angioedema (HAE). It aims to see how safe it is and how well people tolerate it over a long time. Navenibart might help prevent HAE attacks, which can be severe and painful.
Hereditary angioedemaNew Zealand - Active not recruitingNA
Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial
This study looks at whether closing off a small part of the heart called the left atrial appendage (LAA) during heart surgery can help prevent strokes in people at risk. They're comparing it to standard care in those having heart operations.
Ischemic StrokeSystemic EmbolismNew Zealand - RecruitingPHASE3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
This study looks at the long-term safety and effectiveness of a cancer drug called pembrolizumab (and related treatments) for people with advanced cancers. It's for patients who are already receiving these treatments in other studies and want to continue.
Solid TumorsHematologic MalignanciesNew Zealand - Active not recruitingPHASE2
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
This study is testing a new medicine, ENV-101, for people with lung scarring conditions like Idiopathic Pulmonary Fibrosis (IPF). It aims to see if it improves breathing and is safe to use. Patients might continue their usual treatments.
Idiopathic Pulmonary FibrosisProgressive Fibrosing Interstitial Lung DiseaseNew Zealand - Active not recruitingPHASE3
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
This study looks at a new drug, isatuximab, combined with standard treatments (lenalidomide and dexamethasone) for people with high-risk smoldering multiple myeloma. It aims to see if this combination can prevent the disease from getting worse compared to the standard treatments alone.
Plasma Cell MyelomaNew Zealand - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
This study looked at new treatments for HER2-positive breast cancer that had already been treated but still showed signs of cancer after surgery. Researchers wanted to see if adding certain drugs could prevent the cancer from coming back.
Breast CancerNew Zealand - Active not recruitingPHASE1, PHASE2
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
This study looks at new drug combinations for people with certain types of Non-Hodgkin's Lymphoma that have come back or not responded to previous treatments. It aims to check safety and how well the new treatments work.
Lymphoma, Non-HodgkinNew Zealand - Enrolling by invitation
Zoledronate In the Prevention of Paget's Disease: Long Term Extension
This study looks at people with a higher risk of Paget's disease due to genetics. It's an extension of a previous study and aims to see if an early treatment helps prevent symptoms or slow down the disease over five years.
Paget DiseaseNew Zealand - Recruiting
Quality of Pediatric Resuscitation in a Multicenter Collaborative
This study looks at how the quality of CPR given to children during a cardiac arrest affects their recovery. Researchers are observing children in hospitals to see if better CPR techniques and after-care improve survival and brain function.
Cardiac ArrestCardiopulmonary ArrestNew Zealand - RecruitingPHASE3
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
This study looks at a new medicine, BI 764198, for people aged 12 and over with a kidney condition called FSGS. It aims to see if this medicine helps improve kidney health. Participants will take a tablet daily and have their kidney function checked regularly.
Focal Segmental GlomerulosclerosisNew Zealand - Recruiting
Global Prospective, Observational Cohort of Adult Patients With Primary Sclerosing Cholangitis (WIND-PSC Study)
Researchers are studying adults with a liver condition called Primary Sclerosing Cholangitis (PSC) to better understand how it affects people over time. This will help them design better future studies and treatments for PSC.
PSCNew Zealand - Active not recruitingPHASE3
A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)
This study looks at the safety of a two-in-one medicine called DOR/ISL for adults with HIV-1. It's for people who have already taken this medicine in other research studies. The main goal is to see how well people tolerate it over time.
HIV InfectionNew Zealand - Not yet recruitingPHASE3
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
This study is testing a new medicine, nerandomilast, for people with systemic sclerosis. It aims to see if the medicine can improve symptoms and slow the disease. Adults with systemic sclerosis might be able to join this study.
Systemic SclerosisNew Zealand - RecruitingPHASE2, PHASE3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
This study looks at a new drug called adagrasib, on its own and with another drug, pembrolizumab, for people with advanced lung cancer. It's for those with a specific gene change (KRAS G12C) who haven't had treatment yet.
Advanced Non-Small Cell Lung CancerMetastatic Non-Small Cell Lung CancerNew Zealand - RecruitingPHASE2
A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight
This study is testing a new medicine, BI 3034701, to see if it helps adults with obesity or overweight lose weight. Participants will get either the medicine or dummy medicine, plus advice on diet and exercise.
ObesityOverweightNew Zealand - RecruitingPHASE3
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
This study is looking into a new drug, PF-06821497, combined with an existing drug, enzalutamide, for men with advanced prostate cancer. It wants to see if this combination works better than enzalutamide alone for those who haven't had certain other treatments.
Metastatic Castration-Resistant Prostate CancerNew Zealand - Active not recruitingPHASE3
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
This study compares two treatments for chronic lymphocytic leukaemia (CLL), a type of blood cancer. We're looking at whether a new combination (sonrotoclax with zanubrutinib) works better than a standard one (venetoclax with obinutuzumab) in people who haven't had treatment before.
CLLNew Zealand - RecruitingPHASE3
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
This study looks at a long-term treatment called nerandomilast for people with pulmonary fibrosis. It's for those who've used it in a past study. We'll see how safe and effective it is over time, checking if it helps lung function and slows down the disease.
Idiopathic Pulmonary FibrosisProgressive Pulmonary FibrosisNew Zealand - RecruitingPHASE3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
This study looks at a new medicine, vicadrostat, for people with type 2 diabetes, high blood pressure, and heart disease. It aims to see if taking vicadrostat alongside empagliflozin can help reduce heart problems. Half the participants will get the study medicine, and half will get a dummy pill.
Diabetes Mellitus, Type 2HypertensionCardiovascular DiseasesNew Zealand - RecruitingPHASE3
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
This study looks at a new drug, mevrometostat, combined with enzalutamide for men with prostate cancer that has spread. It compares this combination to enzalutamide alone, to see if it works better for those not yet treated with specific hormone therapies.
Metastatic Castration Sensitive Prostate Cancer (mCSPC)Hormone Sensitive Prostate CancerProstate CancerCancer of the ProstateNew Zealand - RecruitingNA
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
This study looks at whether a special feature in a Medtronic pacemaker can help lower high blood pressure. It compares having this feature on versus off in people who either need a pacemaker or already have one and also have high blood pressure.
HypertensionHypertension, SystolicHypertension, EssentialNew Zealand - RecruitingPHASE2, PHASE3
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
This study looks at a new drug, ficerafusp alfa, combined with pembrolizumab (Keytruda®) for people with advanced head and neck cancer. It compares this combination against pembrolizumab alone to see if it works better and is safe.
Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaNew Zealand - Active not recruitingPHASE2
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
This study looks at a new medicine, vicadrostat, combined with empagliflozin, for adults with chronic kidney disease. Participants will take pills daily for 3 months, with regular checks on their kidney health and general well-being. It aims to see if starting medicines at different times impacts results.
Chronic Kidney DiseaseNew Zealand - RecruitingPHASE3
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
This study is looking into a new medicine, BI 1291583, for people with bronchiectasis. It aims to see if this medicine can help reduce flare-ups, which are common with the condition. Participants will take a tablet daily and be monitored for up to 1 year and 8 months.
BronchiectasisNew Zealand - RecruitingPHASE3
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
This study looks at a new medicine called survodutide for adults with a liver condition called MASH and moderate to advanced liver damage. It aims to see if the medicine can improve liver health and how safe it is.
Metabolic Dysfunction Associated Steatohepatitis (MASH)Liver FibrosisNew Zealand - RecruitingPHASE3
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
This study compares two treatments for newly diagnosed multiple myeloma in adults who can't have a stem cell transplant. It aims to see if a combination including Elranatamab is better than another standard combination at controlling the cancer and improving patients' lives.
Multiple MyelomaNew Zealand - RecruitingPHASE2, PHASE3
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
This study is looking at a new medicine, RO7771950, for HER2-positive breast cancer that has spread or is hard to remove. It compares RO7771950 with an existing medicine, tucatinib, both given with trastuzumab and capecitabine. The aim is to see if the new medicine works well and is safe.
HER2-positive Breast CancerNew Zealand - RecruitingPHASE3
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
This study looks at a new medicine called survodutide for adults with a liver condition called NASH or MASH and scarring (cirrhosis). Participants will get either the medicine or a dummy treatment, along with diet and exercise advice, to see if it helps their liver.
Metabolic Dysfunction Associated SteatohepatitisNew Zealand - RecruitingPHASE3
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
This study is for people who have already taken part in other studies for a medicine called sotatercept, used to treat Pulmonary Arterial Hypertension (PAH). It aims to check the long-term safety and how well people tolerate sotatercept when taken with their usual PAH treatments.
Pulmonary Arterial HypertensionNew Zealand - Active not recruitingPHASE3
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
This study looks at a new daily pill, enlicitide decanoate, for people at high risk of heart problems like heart attacks or strokes. It aims to see if this pill can help reduce these serious events safely, compared to a dummy pill.
ArteriosclerosisHypercholesterolaemiaNew Zealand - RecruitingPHASE2
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
This study is testing a new drug, SAB-142, for people with recently diagnosed Type 1 Diabetes. It aims to see if SAB-142 can slow down the disease, and if it's safe to use. Participants will receive high dose, low dose, or a dummy drug.
Type 1 DiabetesNew Zealand - Recruiting
Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study
Researchers are studying Friedreich ataxia to better understand how the condition progresses and to help develop new treatments. This study will follow people with Friedreich ataxia for many years, gathering information about their health and how the condition affects them.
Friedreich AtaxiaNew Zealand - RecruitingPHASE3
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
This study is looking at a new treatment for non-small cell lung cancer after surgery. It combines two medicines, sacituzumab tirumotecan and pembrolizumab, to see if they work better together than pembrolizumab alone in preventing the cancer from coming back.
Non Small Cell Lung CancerNew Zealand - Active not recruitingPHASE2, PHASE3
A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
This study is looking at a new combination of medicines, relatlimab and nivolumab, for advanced melanoma. It aims to see if this combination works better than nivolumab alone for melanoma that has spread or can't be removed by surgery.
MelanomaNew Zealand - RecruitingPHASE3
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
This study looks at a new medicine called felzartamab for adults with a kidney disease called IgA nephropathy (IgAN). Researchers want to see if it reduces protein in the urine and helps kidney function. It involves infusions and careful monitoring.
Immunoglobulin A Nephropathy (IgAN)New Zealand - RecruitingNA
The GORE VBX FORWARD Clinical Study: A Comparison of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis to Bare Metal Stenting for Patients With Complex Iliac Occlusive Disease
This study compares two ways to open narrowed leg arteries using stents. It looks at a newer stent called VBX versus standard bare metal stents for people with blockages in their iliac arteries, aiming to see if the VBX works better to keep the arteries open.
Aortoiliac Occlusive DiseasePeripheral Arterial DiseaseNew Zealand - Active not recruitingPHASE3
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
This study is looking at an RSV vaccine for people aged 60 and over. It aims to find the best time for repeat vaccination, understand long-term protection, and give the vaccine to people who previously received a dummy treatment.
Respiratory Syncytial Virus InfectionsNew Zealand - RecruitingPHASE3
Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain (LOLIPOP) Trial
The LOLIPOP trial is studying a common pain medication called lidocaine, given into a vein during and after breast cancer surgery. We want to see if it helps reduce long-term pain and is safe for patients.
Breast CancerBreast Cancer FemaleBreast Conserving SurgeryMastectomyNew Zealand - Active not recruitingPHASE2
SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.
This study looks at new drug combinations (VIR-2218 and VIR-3434) to treat long-lasting Hepatitis D infection. It's a Phase 2 trial, meaning researchers are checking if these treatments are safe, handleable, and work well in people.
Hepatitis D, ChronicNew Zealand - RecruitingPHASE1, PHASE2
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
This study is testing new treatments, alone or in combination, for advanced prostate cancer that has spread and no longer responds to hormone therapy. Researchers want to see if these treatments are safe and effective in helping men with this condition.
Castration-Resistant Prostatic CancerMetastasisNew Zealand - RecruitingNA
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
This study compares two ways to remove stage II melanoma, using different-sized safety borders (1cm vs. 2cm). It aims to see if a smaller border is just as safe and improves quality of life, without increasing the chance of cancer returning.
Cutaneous Melanoma, Stage IINew Zealand - Active not recruitingPHASE2
A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)
This study is testing new medicines, daplusiran/tomligisiran (DAP/TOM) and bepirovirsen, for people with long-term Hepatitis B. It aims to find the best dose of DAP/TOM to use with bepirovirsen to improve treatment.
Chronic Hepatitis B Virus InfectionHepatitis BNew Zealand